The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Thank you
Company Name: OPEN ORPHAN PLC Company Number: 07514939
Received for filing in Electronic Format on the: 18/06/2021 XA6X1UXD Shares Allotted (including bonus shares)
Date or period during which shares are allotted
Class of Shares:
Currency:
No shares allotted other than for cash
Class of Shares: ORDINARY Currency: GBP
No shares allotted other than for cash
From To
16/06/2021
Number allotted
Nominal value of each share Amount paid:
Amount unpaid:
Number allotted
Nominal value of each share Amount paid:
Amount unpaid:
143312 0.001 0.001
0
261494 0.001 0.022.
Could any body tell me what this means
OPEN ORPHAN PLC
("Open Orphan" or the "Company")
Proposed Distribution in Specie
Notice of Results
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials , announces that, further to previous announcements, it proposes to make a distribution in specie of the entire issued share capital of its wholly-owned subsidiary Orph Pharma IP Company Limited ("Orph Pharma") to Poolbeg Pharma Limited ("Poolbeg"), in return for the issue of new shares by Poolbeg ("Poolbeg Shares") to shareholders of Open Orphan on the register at close of business on 17 June 2021 ("Relevant Shareholders") .
The approval of Open Orphan shareholders to such distribution in specie was granted at Open Orphan's general meeting held on 29 April 2021 .
It is expected that Open Orphan ordinary shares will be marked "ex rights" at 8.00 a.m. on 16 June 2021.
It is also expected that the board of Open Orphan will convene formally to make such distribution in specie on 18 June 2021 and that Relevant Shareholders will receive one Poolbeg Share for every 2.98 ordinary shares held in the Company, with resultant entitlements rounded down to the nearest whole number. Prior to the making of the distribution in specie, Open Orphan and Poolbeg intend to enter into a demerger agreement providing for the issue of the Poolbeg Shares to Relevant Shareholders in return for the distribution in specie of the entire issued share capital of Orph Pharma to Poolbeg.
Further to the Company's announcement of 13 April 2021, the board of Open Orphan has determined that if and when the Poolbeg Shares are admitted to trading on AIM ("Admission") Relevant Shareholders who receive Poolbeg Shares will not be permitted to sell, transfer or deal in such Poolbeg Shares for a period of 9 calendar months (the "Lock-up Period"). Accordingly, Open Orphan and Poolbeg have appointed Croft Nominees Limited ("Croft") to hold the legal title to the Poolbeg Shares from the date on which the distribution in specie is effected until the date which is 9 months from Admission.
Croft has agreed to hold on trust on behalf of Relevant Shareholders, the beneficial owners of the Poolbeg Shares, an omnibus share certificate representing all the Poolbeg Shares until the end of the Lock-up Period and to take certain limited actions with respect to the Poolbeg Shares. Following the expiry of the Lock-up Period Croft will deliver the share certificate to Poolbeg's registrar and will execute stock transfer forms to transfer the Poolbeg Shares to Relevant Shareholders based on a schedule to be provided to Croft by Poolbeg, and upon the registration of such Relevant Shareholders (or their respective personal representative, nominee or successor in title) as legal holders of such shares, Croft will be released from its obligations in relation to such trust arrangements
Soon
OP HOLDCO 2021 LIMITED
Registered office address
Queen Mary Bioenterprises Innovation Centre, 42 New Road, London, United Kingdom, E1 2AX
Company status
Active
Company type
Private limited Company
Incorporated on
26 April 2021
Accounts
First accounts made up to 31 December 2021
due by 30 September 2022
Confirmation statement
First statement date 25 April 2022
due by 9 May 2022
Nature of business (SIC)
72110 - Research and experimental development on biotechnology
Previous company names
Previous company names
Name Period
POOLBEG PHARMA LIMITED 26 Apr 2021 - 08 Jun 2021
TIDMORPH
RNS Number : 0544Z
Open Orphan PLC
19 May 2021
OPEN ORPHAN PLC
("Open Orphan" or the "Company")
Court Approval to facilitate Distribution in Specie
Continued progress towards planned Demerger
Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, confirms that, following its announcement on 13 April 2021, it has received Court approval for the reduction in capital. The reduction of capital will become effective on registration of the Court order at Companies House, which is expected to occur in the next few days.
The reduction of capital will give the Company the ability to not only effect the Distribution in Specie, as part of the proposed spin-out of certain non-core Development IP Assets , but also to make other distributions to Shareholders and/or buy back its own Open Orphan Ordinary Shares in the future if and when the Directors may consider that it is appropriate to do so.
As previously announced, the Board has decided that a spin-out and admission to AIM of the wholly owned Development IP Assets may provide the opportunity to secure separate financial resources for the Development IP Assets, with the goal of enabling accelerated development of the asset portfolio and achievement of development and commercial milestones. The Development IP Assets include HVO-001, an orally available, small molecule immunomodulator drug with potential as a treatment for severe influenza and symptoms requiring treatment in hospital with the drug unaffected by viral heterogeneity. It has the potential to treat a broad range of serious unmet needs in patients suffering from severe and fatal respiratory disease.
It is anticipated that a spin-out pursuant to the Demerger would allow the Company's shareholders to benefit from both the value of the Development IP Assets and the standalone value of the remaining business as it progresses through its own key milestones.
The Company continues to make good progress towards delivering against the potential Demerger and Distribution in Specie and will update shareholders in due course.
Terms defined in the Company's circular dated 13 April 2021 shall have the same meanings in the announcement.
Cathal Friel, Executive Chairman of Open Orphan plc commented: "We are delighted to have received Court approval of the reduction of capital. The reduction of capital will allow us to return value to shareholders as we go forward either as a distribution in specie as part of the proposed spin-off or through a share buy back or a payment of a dividend, as appropriate. The Company and the entire Open Orphan team have made significant progress in the past year and we remain on target with all of our plans as we continue to build the company going forward."
Just executed at 43.11p
Opened isa with ii , put in 19400 pounds and asked them to buy this amount in oo, that was 1 hour ago and still not executed
Open Orphan plc
("Open Orphan" or the "Company")
Potential demerger of certain non-core assets
Proposed Capital Reduction, Distribution in Specie and notice of General Meeting
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces that it is at an advanced stage in planning for a possible spin-out of certain non-core Development IP Assets. These Development IP Assets are a portfoilio of intellectual property and development assets, including HVO-001 which has potential application in the treatment of respiratory disease. These do not include the equity interests in Imutex Limited and PrEP Biopharm Limited.
The Board believes that to maximise shareholder value that the Development IP Assets are best developed separately from the core services business. Furthermore, such a spin-out transaction could provide the opportunity to secure separate financial resources for these assets, to enable accelerated development of these assets and achievement of commercial milestones. A spin-out transaction would also allow Shareholders to benefit from both the value of the development assets and the standalone value of the core services business, as they progress through their own key milestones.
To this end, a circular (a "Circular") is being sent to shareholders today providing background to, details of and reasons for, a proposed Reduction of Capital and Distribution in Specie, to facilitate the possible spin-out and admission to AIM of the Company's non-core Development IP Assets. The reduction in capital will also allow for the Company to pay dividends and distributions to shareholders should the Board deem it appropriate in the future.
The Board has decided to take the necessary preliminary steps in preparation for a potential spin-out, including incorporating a new subsidiary, further details of which are outlined in the Circular. The Company has decided to proceed in obtaining the approvals necessary for the Reduction of Capital and the Distribution in Specie which are required to implement the demerger. Notwithstanding that the Company is seeking the necessary approvals for the Reduction of Capital and the Distribution in Specie now, these considerations remain at an early stage, and there can be no guarantee that the Reduction of Capital and/or the Distribution in Specie will be completed. HMRC advance clearance for the Demerger has been successfully obtained so any distribution would be exempt for income tax purposes and have no capital gains implications for UK shareholders. Further announcements will be made at the appropriate time.
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO , a subsidiary of Open Orphan, has entered into a contract with a biotechnology company to run a human viral challenge study for a r espiratory syncytial virus ("RSV") prophylactic and treatment.
This US biotechnology company is developing a product for the prevention and treatment of acute and chronic r espiratory syncytial virus infections. RSV is a contagious virus that affects the respiratory tract of children and at-risk older adults; in severe cases, it can cause pneumonia and other life-threatening breathing difficulties. RSV is a significant public health threat and is one of the leading causes of hospitalisation of young children across the world. It also poses a significant threat to at-risk older adults; in the current climate, RSV may also lower immunity and increase the risk of developing COVID-19, and where these infections occur together, it can worsen the severity of COVID-19 illness. There is currently no prophylactic or specific treatment on the market for RSV.
The total contract value is GBP7.5m and the study is due to commence in Q4 2021, with the majority of revenues being recognised in 2021. hVIVO will conduct this study on behalf of its client to demonstrate the efficacy of their lead candidate against RSV infection. The product is expected to have substantial advantages with respect to potency, safety, tolerability and convenience while fully maintaining efficacy when compared to other similar products.
Cathal Friel, Executive Chairman, said: "This is another substantial and significant contract win for hVIVO and Open Orphan. Through signing these deals, we continue to reinforce our position as the clear world leader in human challenge studies. Over the past year, Open Orphan has fully restructured, reorganised, and integrated our London, Paris and Breda operations to become a fast-growing, profitable provider of human challenge clinical trials in a manner required by the global pharmaceutical and biotechnology companies. We have expanded from one clinic to multiple clinics, and it is our stated objective to continue to invest and expand our global capability to ensure our position as the world leader in testing vaccines, antivirals, and monoclonal antibodies through the use of human challenge studies well into the future.
With the ongoing expansion of our clinical footprint, we can now provide any pharmaceutical company, anywhere in the world, rapid access to challenge study clinical trials to gather data on their product in a relatively short time period. In the past, human challenge studies suffered from the perception that it was difficult to find a provider and that it may take a long period of time to complete, however, Open Orphan is transforming this view. We are delighted to s
TIDMORPH
RNS Number : 5449R
Open Orphan PLC
09 March 2021
9 March 2021
Open Orphan plc
("Open Orphan" or the "Company")
New contract win with Oxford BioTherapeutics
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its subsidiary Venn Life Sciences ("Venn") has been awarded a contract for a study with Oxford BioTherapeutics, a clinical stage oncology company with a pipeline of immune-oncology and antibody-drug conjugate-based therapies.
This is a phase I, open-label, dose finding study which will be used to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of OBT076, a CD205-directed antibody-drug conjugate, in recurrent and/or metastatic CD205-positive solid tumours and in women with CD205-positive HER2-negative metastatic breast cancer.
For this study, the Venn Paris team will deliver high-quality data management and statistics services. Venn's team in Paris are highly regarded in the field as one of the leading providers in this area which is a perfect complement to the Company's London offering. The study is due to start immediately.
Cathal Friel, Executive Chairman, Open Orphan, commented: "We are delighted to be in a position to announce another contract win for the Paris team. This deal further demonstrates Open Orphan's ability to execute on its significant pipeline of contracts with important pharmaceutical businesses.
"Oxford BioTherapeutics is a clinical stage oncology company with a pipeline of first-in-class therapies aiming to fulfil major unmet patient needs by targeting difficult-to-treat cancers. The Venn team are looking forward to assisting with the study and providing the preliminary data required to advance this breast cancer trial."
Dr Rahim Fandi, MD, PhD Oxford BioTherapeutics CMO commented: "We are delighted to work with Venn and are sure that Oxford BioTherapeutics will benefit from their expertise."
For further information please contact:
The UK must prepare for a “hard winter” since the population could be less immune to other respiratory illnesses such as flu, a top medic has warned.
Speaking to the BBC’s Andrew Marr Show Sunday, Dr Susan Hopkins, Covid-19 strategic response director at Public Health England (PHE), said the country could see surges of other respiratory diseases, as well as coronavirus, come autumn.
It comes as the UK continues to roll out its vaccine program and starts to ease lockdown restrictions with summer approaching.
Asked if the country could be back in a difficult situation by autumn, Hopkins said: “I think it is really difficult to predict what is going to happen in the future and six months away is a long time."
9th feb
Sky news this morning.
The chancellor will also promise to invest a further £33m in vaccine testing and development to protect against future outbreaks and variants.
And there will be another £22m for what the government claims will be a "world-leading study" to test the effectiveness of combinations of different vaccines.
This research on the different use cases for lateral flow antibody tests is welcome,” said Chris Molloy, chair of the UK-RTC.
“The AbC-19 test is an important weapon in the global fight against Covid-19. It allows us to see the neutralising IgG antibodies produced in response to infection, or after vaccination.”
Shares in Omega closed more than 16% higher yesterday on the news, up 13p at 93p.
The results come after Prime Minister outlined the important role that lateral flow tests could play in reviving the UK economy. In his Covid-19 briefing on Monday evening, Boris Johnson said that he hopes people will be able to return to nightclubs and theatres through the use of rapid Covid-19 tests.
READ MORE: Omega confirms Covid testing contract
Last week, Omega confirmed that it has been chosen to help supply the UK Department of Health and Social Care (DHSC) with millions of lateral flow antigen tests for Covid-19. The intention is that once the DHSC has access to a test that has successfully passed a performance evaluation, it will be licensed to Omega for manufacture.
The company is ramping up capacity at its headquarters in Alva to produce approximately two million tests per week by the end of April. Omega’s house analyst, FinnCap, has said this could generate between £150 million and £200m of additional annual revenues for the Scottish company.
Staff headcount at Alva has increased from 60 to more than 120 people.
This research on the different use cases for lateral flow antibody tests is welcome,” said Chris Molloy, chair of the UK-RTC.
“The AbC-19 test is an important weapon in the global fight against Covid-19. It allows us to see the neutralising IgG antibodies produced in response to infection, or after vaccination.”
Shares in Omega closed more than 16% higher yesterday on the news, up 13p at 93p.
The results come after Prime Minister outlined the important role that lateral flow tests could play in reviving the UK economy. In his Covid-19 briefing on Monday evening, Boris Johnson said that he hopes people will be able to return to nightclubs and theatres through the use of rapid Covid-19 tests.
READ MORE: Omega confirms Covid testing contract
Last week, Omega confirmed that it has been chosen to help supply the UK Department of Health and Social Care (DHSC) with millions of lateral flow antigen tests for Covid-19. The intention is that once the DHSC has access to a test that has successfully passed a performance evaluation, it will be licensed to Omega for manufacture.
The company is ramping up capacity at its headquarters in Alva to produce approximately two million tests per week by the end of April. Omega’s house analyst, FinnCap, has said this could generate between £150 million and £200m of additional annual revenues for the Scottish company.
Staff headcount at Alva has increased from 60 to more than 120 people.
Provisional research has shown that the rapid Covid-19 test in which Scotland’s Omega Diagnostics is involved has an accuracy of more the 97 per cent, the highest of four such tests that were reviewed.
The study, performed by scientists at Public Health England (PHE), has yet to be evaluated by the medical community as part of the usual peer review process and could therefore contain errors in its assumptions and methods. However, it was welcomed by the chairman of the UK Rapid Test Consortium (UK-RTC), of which Omega is a member.
The consortium’s AbC-19 lateral flow test uses a small drop of blood from a finger prick to determine within 20 minutes whether a person has antibodies to fend off Covid-19. The study by PHE, in conjunction with the universities of Bristol, Warwick and Cambridge,
I believe that if he has price sensitive information, which is very likely considering all the contractors being negotiated he is not allowed to purchase shares because this would be considered insider dealing
RNS Number : 7839N
Open Orphan PLC
03 February 2021
Open Orphan plc
("Open Orphan" or the "Company")
New challenge study quarantine clinic
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services contract research organization (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, part of Open Orphan plc, has opened a new quarantine clinic in East London. The new site is based in Whitechapel, directly opposite the Queen Mary BioEnterprise Innovation Centre ("QMB") which houses hVIVO's 24 bedroom unique state-of-the-art FluCamp site and the recently opened new street-level volunteer screening centre. The Whitechapel Clinic will act as an extension of hVIVO`s current QMB site.
The converted 26-bedroom former boutique hotel, which will be known as the Whitechapel Clinic, has the capacity for up to 19 quarantine rooms and will be used as an additional unit for human challenge trials and volunteer recruitment screening. The quarantine rooms are located across three floors of the former hotel, with each level fully converted to include a nurses station on each floor.
The new site, like QMB, will follow the highest safety standards to deliver each clinical study and volunteer screening visit. Of the 19 rooms, 8 rooms on a single floor are flexible use clinic rooms, meaning they can be used as either quarantine bedrooms for challenge studies or for volunteer screening visits. Each room at the facility has been fully repurposed to the highest standard, with all volunteer rooms equipped with an en-suite bathroom, TV, wardrobe, and tea & coffee making facilities. This will provide a comfortable space for volunteers during studies. The Whitechapel Clinic, like QMB, is also equipped with a 24-hour security presence and a working hour reception desk.
Cathal Friel, Exexcutive Chairman of Open Orphan plc commented: "Our newest quarantine unit greatly increases our capacity to facilitate hVIVO's pipeline of upcoming studies. Our QMB clinic is now close to full capacity until December 2021, and as such, the newly renovated, state of the art Whitechapel Clinic will allow us to increase our study capacity substantially in the year ahead.
"We have leased the entire former Whitechapel Hotel and managed to convert the space on a very cost efficient basis which is now almost fully booked to capacity for H1 2021. This new facility will be run at the same high standard as our QMB site, and volunteers will be expertly supervised by our highly trained nurses and doctors in a safe and controlled clinical environment."
Interested in becoming a volunteer?